Abstract 4317
Background
Adenocarcinoma of esophagogastric junction (AEG) is a special type of malignant tumor which occurs in the upper gastrointestinal tract. However, AEG is different from esophageal or gastric cancer. Its biological behavior is complicated and prognosis is poor. Even after radical resection, the overall 5-year survival rate is still very low. An in-depth analysis of the prognostic factors in patients with AEG may indicate a certain direction for clinical treatment and decision-making as well as for improving the prognosis of patients with AEG. Although some researchers have explored the factors influencing the prognosis of AEG, the independent prognostic factors are still unclear, which need to be further studied.
Methods
The clinical data of patients with AEG who underwent surgical treatment in PLA general hospital from January 2009 to January 2013 were collected retrospectively. According to the inclusion and exclusion criteria, a total of 343 patients with AEG were included in the study. Sex, age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, approach, minimally invasive surgery, resection scope, adjuvant chemotherapy, HER-2 and Ki-67 expression were analyzed comprehensively to study the independent or nonindependent prognostic factors in patients with AEG.
Results
The median follow-up time of the 343 patients with AEG was 50.2 months. The 5-year overall survival rate of the whole group (no IV stage) was 49.2%. Univariate analysis showed that age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, adjuvant chemotherapy, level of Ki-67 expression was correlated with prognosis (P < 0 05). Multivariate analysis showed that age, tumor size(Diameter), differentiation, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival of the patients (P < 0 05).
Conclusions
The age, tumor size (Diameter), differentiation degree, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival rate of patients with AEG (P < 0 05).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3668 - Patient Demographics and Management Landscape of Metastatic Colorectal Cancer in the Third Line Setting: real-world data in an Australian Population
Presenter: Sandy Tun Min
Session: Poster Display session 2
Resources:
Abstract
3907 - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Presenter: Axel Grothey
Session: Poster Display session 2
Resources:
Abstract
3958 - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey
Presenter: Zorana Maravic
Session: Poster Display session 2
Resources:
Abstract
3563 - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal
Presenter: Rachel Riechelmann
Session: Poster Display session 2
Resources:
Abstract
1184 - iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Presenter: Fiona Turkes
Session: Poster Display session 2
Resources:
Abstract
3346 - Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Presenter: Lisa Salvatore
Session: Poster Display session 2
Resources:
Abstract
3895 - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.
Presenter: Maria Aurelia Barbera
Session: Poster Display session 2
Resources:
Abstract
2012 - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT
Presenter: Josep Tabernero
Session: Poster Display session 2
Resources:
Abstract
2198 - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Presenter: Thierry Andre
Session: Poster Display session 2
Resources:
Abstract
2921 - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)
Presenter: Mark Saunders
Session: Poster Display session 2
Resources:
Abstract